Following on from information provided to NICE by the company in March 2011, the appraisal of Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 333 |
| Referral date | 01 April 2010 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Tonya Gillis |
| Executive Lead: | Andrew Dillon |
| Project manager: | Jeremy Powell |
| Technical Lead: | Whitney Miller |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2011, the appraisal of Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 March 2011 |
The manufacturer has informed us that they will not be seeking a license for this particular indication at the present time. NICE has therefore decided to suspend this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.” |
For further information on our processes and methods, please see our CHTE processes and methods manual